442517-35-3

Upstream product

• 5315-25-3 2-bromo-6-methylpyridine 
• 442517-33-1 6-ethynylquinoxaline 

Downstream Products

• 710946-99-9 4-[4-(6-methyl-pyridin-2-yl)-5-quinoxalin-6-yl-[1,2,3]triazol-2-ylmethyl]-benzonitrile 
• 710947-10-7 4-[4-(6-methyl-pyridin-2-yl)-5-quinoxalin-6-yl-[1,2,3]triazol-2-yl]-benzonitrile 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor

A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 8d showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5μM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38α MAP kinase inhibition (13%) at a concentration of 10μM that is much lower than that of SB-431542 (54%).